2017-06-21 19:37:29 UTC

Considerations in Use of Biosimilars for Gastrointestinal Disorders


.5 hours


In this on demand webcast, Stephen B. Hanauer, MD, AGAF and David T. Rubin, MD, AGAF provide an overview of the current body of knowledge on the safety and efficacy of biosimilar products. Biosimilar pricing is explored, as well as the impact of payor decisions on clinical GI practice. This activity is a collaboration of the AGA Institute and the Crohn's and Colitis Foundation.

This program is supported by independent educational grants from Boehringer Ingelheim Pharmaceuticals, Inc. and Pfizer Inc.

Who Should Take this Course

This activity is intended for gastroenterologists, GI fellows, nurse practitioners, physician assistants and other healthcare professionals who treat GI disorders.

Learning Objectives

At the conclusion of this presentation, learners will:

  • Appreciate the landscape that has contributed to the emergence of biosimilars in the U.S. IBD market
  • Gain clarity on the definition of biosimilars and the abbreviated FDA approval pathway
  • Appreciate the rationale for extrapolation of indications
  • Know that no biosimilar has received an interchangeable designation
  • Consider the clinical scenarios in which biosimilars may be utilized safely


Claim CME

CME Information

The American Gastroenterological Association (AGA) Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The AGA Institute designates this enduring activity for a maximum of .5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

In accordance with the ACCME’s Standards for Commercial Support of Continuing Medical Education, all faculty and planning partners must disclose any financial relationship(s) or other relationship(s) held within the past 12 months. The AGA Institute implements a mechanism to identify and resolve all conflicts of interest prior to delivering the educational activity to learners.

CME expiration date: July 19, 2019

Faculty Relationship and Financial Disclosures

Click here to view financial disclosures for presenters

Planning Committee

Gary R. Lichtenstein, MD, AGAF

Consultant: Abbvie, Alaven, Celgene/Santarus/Receptos, Ferring, Hospira, Janssen Orthobiotech, Luitpold/American Reagent, Pfizer, Prometheus, Salix Pharmaceuticals,

Shire, Takeda, UCB

Grant/Research Support: Celgene/Santarus/Receptos, Takeda

Honoraria: Clinical Advances in Gastroenterology, Ironwood, McMahon Publishing,

Merck, Romarck, Springer

Royalty: SLACK, Inc.

AGA Staff

Maura H. Davis

Disclosed no relevant financial relationships.

Monique S. Dyson, MS, CHES

Disclosed no relevant financial relationships.

Alison Kim, PhD

Disclosed no relevant financial relationships.

Crohn’s & Colitis Foundation Staff

Orna Ehrlich

Disclosed no relevant financial relationships.

Laura Wingate

Disclosed no relevant financial relationships.


Additional Resources

More on Biosimilars

Insurance Barriers Should Not Hinder Step Therapy Treatment for IBD

Dec. 13, 2017

AGA participated in a congressional briefing to highlight the need for physician use of step therapy treatment without barriers.

Get Your Questions Answered on Biosimilar Therapies

Dec. 7, 2017

Join inflammatory bowel disease (IBD) experts on Dec. 11, 2017, 8-8:45 p.m. ET, for a free webinar on biosimilar therapies.

Can You Explain Biosimilars to Patients?

Oct. 25, 2017

AGA is taking the lead in educating health care professionals and their patients about biosimilars and how they can play a role in IBD patient care.